Quidel Corporation (QDEL): Price and Financial Metrics

Quidel Corporation (QDEL): $73.04

1.17 (+1.63%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

QDEL Price/Volume Stats

Current price $73.04 52-week high $102.00
Prev. close $71.87 52-week low $66.88
Day low $72.03 Volume 466,300
Day high $73.57 Avg. volume 460,278
50-day MA $78.62 Dividend yield N/A
200-day MA $84.73 Market Cap 4.88B

QDEL Stock Price Chart Interactive Chart >

QDEL POWR Grades

  • QDEL scores best on the Value dimension, with a Value rank ahead of 91.45% of US stocks.
  • QDEL's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • QDEL ranks lowest in Momentum; there it ranks in the 5th percentile.

QDEL Stock Summary

  • QDEL's current price/earnings ratio is 106.08, which is higher than 95.2% of US stocks with positive earnings.
  • In terms of twelve month growth in earnings before interest and taxes, QUIDELORTHO CORP is reporting a growth rate of -84.57%; that's higher than just 16.46% of US stocks.
  • In terms of volatility of its share price, QDEL is more volatile than merely 9.4% of stocks we're observing.
  • Stocks that are quantitatively similar to QDEL, based on their financial statements, market capitalization, and price volatility, are CARS, OPK, ISPC, EVCM, and SANW.
  • QDEL's SEC filings can be seen here. And to visit QUIDELORTHO CORP's official web site, go to www.quidel.com.

QDEL Valuation Summary

  • QDEL's price/earnings ratio is 106.1; this is 297.38% higher than that of the median Healthcare stock.
  • Over the past 243 months, QDEL's price/earnings ratio has gone down 76.6.

Below are key valuation metrics over time for QDEL.

Stock Date P/S P/B P/E EV/EBIT
QDEL 2023-09-22 1.5 1 106.1 35.5
QDEL 2023-09-21 1.5 1 106.4 35.6
QDEL 2023-09-20 1.6 1 108.8 36.1
QDEL 2023-09-19 1.6 1 112.2 36.9
QDEL 2023-09-18 1.6 1 111.1 36.6
QDEL 2023-09-15 1.6 1 112.2 36.9

QDEL Growth Metrics

    The 4 year price growth rate now stands at 535.53%.
  • Its 5 year net cashflow from operations growth rate is now at 232.27%.
  • The 3 year price growth rate now stands at 69.63%.
Over the past 52 months, QDEL's revenue has gone up $2,761,413,000.

The table below shows QDEL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 3,266 885.3 548.7
2022-09-30 3,036.326 1,037.277 809.753
2022-06-30 2,762.262 1,124.036 1,006.305
2022-03-31 2,325.472 721.384 1,006.078
2021-12-31 1,698.551 805.869 704.226
2021-09-30 1,870.887 923.623 883.039

QDEL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • QDEL has a Quality Grade of B, ranking ahead of 85.03% of graded US stocks.
  • QDEL's asset turnover comes in at 1.046 -- ranking 21st of 680 Pharmaceutical Products stocks.
  • SYRS, ONVO, and SESN are the stocks whose asset turnover ratios are most correlated with QDEL.

The table below shows QDEL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.046 0.813 1.894
2021-03-31 1.203 0.825 2.292
2020-12-31 1.314 0.812 2.053
2020-09-30 0.980 0.739 1.094
2020-06-30 0.705 0.663 0.537
2020-03-31 0.625 0.614 0.329

QDEL Price Target

For more insight on analysts targets of QDEL, see our QDEL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $127.75 Average Broker Recommendation 1.8 (Moderate Buy)

Quidel Corporation (QDEL) Company Bio


Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, women’s health, and gastrointestinal diseases. The company was founded in 1979 and is based in San Diego, California.


QDEL Latest News Stream


Event/Time News Detail
Loading, please wait...

QDEL Latest Social Stream


Loading social stream, please wait...

View Full QDEL Social Stream

Latest QDEL News From Around the Web

Below are the latest news stories about QUIDELORTHO CORP that investors may wish to consider to help them evaluate QDEL as an investment opportunity.

QuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS Antigen+ FIA

SAN DIEGO, September 21, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted CLIA Waiver from the U.S. Food and Drug Administration (FDA), applying to its new Sofia® 2 SARS Antigen+ FIA. The Sofia 2 SARS Antigen+ FIA is the first rapid antigen test that detects COVID-19 to be awarded FDA market clearance t

Yahoo | September 21, 2023

Should You Add QuidelOrtho (QDEL) to Your Portfolio?

ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Value Strategy” second quarter 2023 investor letter. A copy of the same can be downloaded here. The strategy outperformed the Russell 2000 value Index in the second quarter. On an absolute basis, the strategy gained all 11 sectors it invested in during the quarter. IT […]

Yahoo | September 21, 2023

QuidelOrtho to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

SAN DIEGO, August 28, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 12, 2023.

Yahoo | August 28, 2023

QuidelOrtho Reports Second Quarter 2023 Financial Results

SAN DIEGO, August 08, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the second quarter ended July 2, 2023.

Yahoo | August 8, 2023

QuidelOrtho Ranks No. 1 in Customer Satisfaction for Six Years in a Row

SAN DIEGO, July 25, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has earned the No. 1 ranking in the diagnostics industry for Overall Customer Satisfaction in the 2023 IMV ServiceTrak Awards for the sixth consecutive year. The ranking is based on interviews conducted with laboratory professionals, including QuidelO

Yahoo | July 25, 2023

Read More 'QDEL' Stories Here

QDEL Price Returns

1-mo -12.66%
3-mo -12.26%
6-mo -17.78%
1-year 2.18%
3-year -67.62%
5-year 13.45%
YTD -14.74%
2022 -36.54%
2021 -24.86%
2020 139.44%
2019 53.69%
2018 12.62%

Continue Researching QDEL

Here are a few links from around the web to help you further your research on Quidel Corp's stock as an investment opportunity:

Quidel Corp (QDEL) Stock Price | Nasdaq
Quidel Corp (QDEL) Stock Quote, History and News - Yahoo Finance
Quidel Corp (QDEL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!